MTOR and cancer: GBM typically expresses p53 with a wild-type amino acid sequence; the reactivation of p53 functionality in cancer cells can be achieved through the blockade of the oncogenic inhibition caused by the AKT/mTOR pathway, which in turn, triggers the undesired excessive stimulation of MDM2.